Department of Neurology, University of North Carolina Health Care , Chapel Hill, NC , USA.
Front Neurol. 2013 Aug 5;4:111. doi: 10.3389/fneur.2013.00111. eCollection 2013.
With the advent of new antiepileptic drugs comes the potential for significant advances in the emergent management of status epilepticus. Traditional antiepileptic drugs possess side effect profiles that may limit their clinical utility or lead to increased patient morbidity or mortality. The relatively recent development of levetiracetam shows promise for effective control of acute status epilepticus in adults, but current objective data of its use as a first-line agent for control of status is quite limited. This paper serves to examine existing literature while considering levetiracetam as a first-line therapy in status in the adult patient population. Although existing studies are narrow in their scope, the present data lay a substantial foundation for further investigation of levetiracetam as a primary therapy in acute status epilepticus.
随着新型抗癫痫药物的出现，癫痫持续状态的紧急处理可能会取得重大进展。传统的抗癫痫药物具有可能限制其临床应用或导致患者发病率或死亡率增加的副作用谱。左乙拉西坦的相对近期发展显示出对成人急性癫痫持续状态有效控制的潜力，但目前作为控制癫痫持续状态的一线药物使用的客观数据非常有限。本文旨在检查现有文献，同时考虑将左乙拉西坦作为成人患者癫痫持续状态的一线治疗。尽管现有研究的范围较窄，但目前的数据为进一步研究左乙拉西坦作为急性癫痫持续状态的主要治疗方法奠定了坚实的基础。
